🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The stomach is an organ unique in its function, environment and exposures. How does this affect the mutations that normal cells in the stomach acquire? What does this reveal about the origins of stomach cancer? These questions and more in our Nature paper: nature.com/articles/s4158…

PAPER OUT!! 🥳🎉💃🏻🕺🏻💃🏻🕺🏻 A redefined InDel taxonomy provides insights into mutational signatures ⁦Nature Genetics⁩ Brainchild of the amazing ⁦Gene C. Koh⁩ Tweetorial below!! 👇 1/n nature.com/articles/s4158…

Stromal mutations occur, but hard to prove they are functional. In our new paper with Trey Ideker’s lab and led by Dr. Mohita Tagore and Maayan Baron, we show that we can find these by looking for mutations across a “class” of genes rather than single genes: nature.com/articles/s4158…

Thrilled to share our latest study just out in nature 😄A major milestone in our collaboration with ⁦Anirban Maitra⁩ Led by brilliant ⁦⁦⁦Guangsheng Pei⁩ ⁦⁦⁦⁦⁦⁦⁦⁦⁦⁦⁦Jimin Min⁩ ⁦⁦MD Anderson Cancer Center⁩ nature.com/articles/s4158…

🚨Thrilled to share our latest work: “Tumor-Infiltrating Clonal Hematopoiesis” NEJM - we investigated how age-related blood mutations impact cancer when they infiltrate tumors, with Elsa Bernard Maria Zagorulya, Elli Papaemmanuil, PhD Charles Swanton + more nejm.org/doi/full/10.10…

Nature research paper: Genomic and genetic insights into Mendel’s pea genes go.nature.com/3EERDat

🧵1/ Can systematic biopsies during RFA improve how we diagnose & manage hepatocellular carcinoma (HCC)? Our study was recently published in J hep reports. Here's what we found 👇 jhep-reports.eu/article/S2589-…

Jessica Zucman Rossi & Théo Hirsh conclude the #EASLCongress BSS on day 1 with an integrated view of personalised medicine in HCC & hepatoblastoma. 🔝👌🏼 Much more basic/translational sessions on days 2-4; check the EASL website/app! EASLnews #livertwitter

Thank you EASLnews for giving me the opportunity to present our work on hepatoblastoma genomics and future therapies together with my mentor Jessica Zucman-Rossi

We extend our heartfelt congratulations to Jessica Zucman-Rossi, University of Paris Cité, France, for her EASL Recognition Award 2025, presented at #EASLCongress. 👏 "Jessica is committed to helping and guiding people, in particular, actively supporting the career development

Fantastic paper from Ben Creelan, MD lab showing subclonal neoantigen loss in tumours progressing on TIL therapy highlighting importance of targeting clonal neoantigens - watch this space for Darwin2 trial reported ESMO - Eur. Oncology by Crispin Hiley Nicholas McGranahan

A triumph of perseverance from twitterless Tom Weber, Christine Biben and the team, our in vivo barcoding "LoxCode mouse" used to resolve epiblast fate to fetal organs is finally published in Cell and available to import through The Jackson Laboratory sciencedirect.com/science/articl…

I’m excited, relieved, and honored to announce that my paper describing non-canonical mitotic mechanisms in the early mouse embryo is out in Science Magazine ! (link at end of 🧵)

In Nature Genetics we report that base editing of trinucleotide repeats (TNRs) reduces somatic repeat expansions in Huntington’s disease (HD) and Friedreich’s ataxia (FRDA)—in patient-derived cells and in vivo—a collaboration with the Mouro Pinto lab. drive.google.com/file/d/1on7kdy… 1/14

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Thank you so much to the Fibrolamellar Cancer for the invitation to the fibrolamellar scientific summit in Greenwich! It was an honor to meet this great community of scientists, physicians and patients. A lot of fruitful discussions and I hope some new collaborations!

Check out my editorial about immune exclusion in hepatoblastoma and a possible role of beta-catenin sciencedirect.com/science/articl…

vib.be/en#/news/resea… Unexpectedly, we find that natural killer (NK) cells, long seen as cancer-fighting allies, can stand in the way of immunotherapy in immune excluded cancer lesions. Thanks to fantastic collaborators O Bechter, Y Saeys, D Lambrechts, Z Li and P Matthys.